In8Bio (INAB) Research & Development (2020 - 2026)
In8Bio (INAB) posted Research & Development of $2.6 million for Q1 2026, down 60.17% sequentially from $6.6 million in Q4 2025, and down 12.08% YoY from $3.0 million in Q1 2025.
In8Bio (INAB) Research & Development (2020 - 2026) Analysis & Trends
In8Bio has reported Research & Development for 7 years, with the latest figure at $2.6 million in Q1 2026.
- Quarterly Research & Development fell 12.08% year-over-year to $2.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.6 million (down 46.99% YoY) and the FY2025 annual result came in at $10.2 million, down 39.8% from the prior year.
- Research & Development eased to $2.6 million in Q1 2026 per INAB's latest filing, from $6.6 million in the prior quarter.
- Over five years, Research & Development peaked at $10.4 million in Q4 2024 and troughed at -$3.8 million in Q4 2023.
- A 5-year average of $3.4 million and a median of $3.5 million in 2022 frame the typical range for Research & Development.
- The sharpest annual moves came in 2023 and 2024: Research & Development sank 197.45% in 2023, then jumped 371.56% in 2024.
- Over 5 years, Research & Development stood at $3.9 million in 2022, then tumbled by 197.45% to -$3.8 million in 2023, then surged by 371.56% to $10.4 million in 2024, then slumped by 36.8% to $6.6 million in 2025, then sank by 60.17% to $2.6 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $2.6 million, $6.6 million, and $1.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | In8Bio | 22.97 Mn | 22.97 Mn | - | 2.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.49 Mn |
| Mar 31, 2026 | 2.61 Mn |
| Dec 31, 2025 | 6.56 Mn |
| Sep 30, 2025 | 1.15 Mn |
| Jun 30, 2025 | 1.24 Mn |
| Mar 31, 2025 | 2.97 Mn |
| Dec 31, 2024 | 10.38 Mn |
| Sep 30, 2024 | 3.31 Mn |
| Jun 30, 2024 | 5.16 Mn |
| Mar 31, 2024 | 2.52 Mn |
| Dec 31, 2023 | -3.82 Mn |
| Sep 30, 2023 | 3.79 Mn |
| Jun 30, 2023 | 4.13 Mn |
| Mar 31, 2023 | 4.39 Mn |
| Dec 31, 2022 | 3.92 Mn |
| Sep 30, 2022 | 4.26 Mn |
| Jun 30, 2022 | 3.50 Mn |
| Mar 31, 2022 | 2.38 Mn |
| Dec 31, 2021 | 2.69 Mn |
| Sep 30, 2021 | 1.35 Mn |